Helicase-Primase as a Target of New Therapies for Herpes Simplex Virus Infections

Single nucleotide polymorphisms of thymidine kinase and DNA polymerase genes in clinical herpes simplex virus type 1 isolates associated with different resistance phenotypes

(2014) Axel Schubert et al.   ANTIVIRAL RESEARCH

Helicase–Primase Inhibitor Pritelivir for HSV-2 Infection

(2014) Anna Wald et al.   NEW ENGLAND JOURNAL OF MEDICINE

Antiviral drug resistance in herpesviruses other than cytomegalovirus

(2014) Jocelyne Piret et al.   REVIEWS IN MEDICAL VIROLOGY

Current and future therapies for herpes simplex virus infections: mechanism of action and drug resistance

(2014) Scott H James et al.   Current Opinion in Virology

Baseline sensitivity of HSV-1 and HSV-2 clinical isolates and defined acyclovir-resistant strains to the helicase–primase inhibitor pritelivir

(2013) Hugh J. Field et al.   ANTIVIRAL RESEARCH

Herpes simplex virus drug-resistance

(2013) Graciela Andrei et al.   CURRENT OPINION IN INFECTIOUS DISEASES

The DNA helicase–primase complex as a target for herpes viral infection

(2013) Sandra K Weller et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Heterogeneity and Evolution of Thymidine Kinase and DNA Polymerase Mutants of Herpes Simplex Virus Type 1: Implications for Antiviral Therapy

(2013) Graciela Andrei et al.   JOURNAL OF INFECTIOUS DISEASES

Acyclovir Prophylaxis Predisposes to Antiviral-Resistant Recurrent Herpetic Keratitis

(2013) Monique van Velzen et al.   JOURNAL OF INFECTIOUS DISEASES

Seroprevalence of Herpes Simplex Virus Types 1 and 2--United States, 1999-2010

(2013) H. Bradley et al.   JOURNAL OF INFECTIOUS DISEASES

Pharmacokinetics and Pharmacodynamics of ASP2151, a Helicase-Primase Inhibitor, in a Murine Model of Herpes Simplex Virus Infection

(2012) Kiyomitsu Katsumata et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Impact of novel mutations of herpes simplex virus 1 and 2 thymidine kinases on acyclovir phosphorylation activity

(2012) Sonia Burrel et al.   ANTIVIRAL RESEARCH

Synergistic activity of amenamevir (ASP2151) with nucleoside analogs against herpes simplex virus types 1 and 2 and varicella-zoster virus

(2012) Koji Chono et al.   ANTIVIRAL RESEARCH

ASP2151 for the Treatment of Genital Herpes: A Randomized, Double-Blind, Placebo- and Valacyclovir-Controlled, Dose-Finding Study

(2012) Stephen Tyring et al.   JOURNAL OF INFECTIOUS DISEASES

Herpes Simplex Viruses: Mechanisms of DNA Replication

(2012) S. K. Weller et al.   Cold Spring Harbor Perspectives in Biology

CMX001 Potentiates the Efficacy of Acyclovir in Herpes Simplex Virus Infections

(2011) Mark N. Prichard et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Efficacy of ASP2151, a helicase–primase inhibitor, against thymidine kinase-deficient herpes simplex virus type 2 infection in vitro and in vivo

(2011) Takehiro Himaki et al.   ANTIVIRAL RESEARCH

Effect of ASP2151, a Herpesvirus Helicase-Primase Inhibitor, in a Guinea Pig Model of Genital Herpes

(2011) Kiyomitsu Katsumata et al.   MOLECULES

Oral Acyclovir Suppression and Neurodevelopment after Neonatal Herpes

(2011) David W. Kimberlin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Progress in the development of new therapies for herpesvirus infections

(2011) Nathan B Price et al.   Current Opinion in Virology

Resistance of Herpes Simplex Viruses to Nucleoside Analogues: Mechanisms, Prevalence, and Management

(2010) Jocelyne Piret et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Effects of therapy using a helicase–primase inhibitor (HPI) in mice infected with deliberate mixtures of wild-type HSV-1 and an HPI-resistant UL5 mutant

(2010) Soumi Sukla et al.   ANTIVIRAL RESEARCH

Antiviral drug resistance and helicase–primase inhibitors of herpes simplex virus

(2010) Hugh J. Field et al.   DRUG RESISTANCE UPDATES

Mismatch primer-based PCR reveals that helicase-primase inhibitor resistance mutations pre-exist in herpes simplex virus type 1 clinical isolates and are not induced during incubation with the inhibitor

(2010) S. Sukla et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

ASP2151, a novel helicase-primase inhibitor, possesses antiviral activity against varicella-zoster virus and herpes simplex virus types 1 and 2

(2010) K. Chono et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Association between the Herpes Simplex Virus-1 DNA Polymerase and Uracil DNA Glycosylase

(2010) Federica Bogani et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Coordinated Leading and Lagging Strand DNA Synthesis by Using the Herpes Simplex Virus 1 Replication Complex and Minicircle DNA Templates

(2010) G. Stengel et al.   JOURNAL OF VIROLOGY

Antiretroviral therapy and management of HIV infection

(2010) Paul A Volberding et al.   LANCET

Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity: Current state of the art

(2009) Karl Y. Hostetler   ANTIVIRAL RESEARCH

Current status and challenges of antiretroviral research and therapy

(2009) José A. Esté et al.   ANTIVIRAL RESEARCH

A mutation in helicase motif IV of herpes simplex virus type 1 UL5 that results in reduced growth in vitro and lower virulence in a murine infection model is related to the predicted helicase structure

(2009) S. Biswas et al.   JOURNAL OF GENERAL VIROLOGY

Efficacy of a Helicase-Primase Inhibitor in Animal Models of Ocular Herpes Simplex Virus Type 1 Infection

(2008) Herbert E. Kaufman et al.   JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS